Tesamorelin Guide — What It Is, How It Works & What the Research Shows

What it is

Tesamorelin, sold as Egrifta (and later formulations EGRIFTA SV and EGRIFTA WR), is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH). It was approved by the U.S. FDA in November 2010, making it the first and only medication approved specifically to reduce excess visceral (deep abdominal) fat in adults with HIV who have lipodystrophy.

Lipodystrophy is an abnormal redistribution of body fat that can occur in people living with HIV, often piling fat around the abdominal organs. Tesamorelin is given as a once-daily subcutaneous injection to target that visceral fat.

Everything beyond HIV-associated lipodystrophy — general belly-fat loss, anti-aging, cognition, or 'research' use — is off-label or investigational. Grey-market 'research' tesamorelin sold online is NOT the FDA-approved drug and is not made, tested, or regulated to pharmaceutical standards.

How it works

GHRH is the natural signal your hypothalamus sends to the pituitary gland to release growth hormone (GH). Tesamorelin is a stabilized GHRH analog engineered to survive in the bloodstream long enough to reach the pituitary and trigger a physiologic, pulse-like release of your own GH — rather than injecting GH directly.

That extra GH raises IGF-1 and promotes lipolysis, the breakdown of stored fat. Because visceral fat is especially GH-sensitive, tesamorelin preferentially trims deep abdominal fat. In the HIV cognition-adjacent trial, IGF-1 rose about 117% on treatment, illustrating how strongly it activates the GH axis.

What people research it for

Reduces visceral (deep belly) fat

Human studies

In pooled Phase 3 HIV trials, 2 mg daily cut visceral adipose tissue roughly 15-18% versus placebo at 26 weeks — the basis for FDA approval.

Raises IGF-1 / restores GH pulses

Human studies

Stimulates the body's own growth hormone rather than replacing it, increasing IGF-1 substantially.

May support cognition in aging

Early human data

A 20-week trial in older adults (some with mild cognitive impairment) found modest gains in executive function and a trend for verbal memory.

Modest body-composition shifts

Early human data

Small decreases in total body fat and increases in lean mass were seen alongside the cognition study; not an approved use.

What the research actually shows

Approval rested on two large randomized, placebo-controlled Phase 3 trials in adults with HIV-associated abdominal fat accumulation. Pooled data (about 800 participants) showed roughly 15-18% CT-measured reduction in visceral adipose tissue at 26 weeks, largely sustained to 52 weeks in those who continued.

The cognition interest comes mainly from a 2012 randomized, double-blind trial (Baker et al., Archives of Neurology, 152 adults) where 20 weeks of GHRH/tesamorelin improved executive function, with a smaller memory signal. It was a short, single study — promising but far from proof of an anti-dementia effect.

Honest limits: benefits (especially fat loss) largely reverse when the drug is stopped, long-term outcome data outside HIV are thin, and the cognition and general-metabolic claims remain investigational, not approved.

Research handling & storage

The pharmaceutical product ships as a lyophilized (freeze-dried) powder that must be reconstituted with the supplied sterile diluent (or, per newer EGRIFTA WR/SV instructions, sterile water) immediately before a once-daily subcutaneous injection into the abdomen. Unmixed vials are refrigerated; mixed drug is used promptly and not stored long.

Dosing here is described only for context: the approved HIV regimen is 2 mg subcutaneously once daily. This is not a prescription or dosing recommendation — appropriate use requires a licensed prescriber, and grey-market powders have unknown identity, purity, and sterility.

Safety & cautions

Common effects in trials included injection-site reactions (redness, itching, pain — about 25% vs 14% placebo), arthralgia (joint pain) and other joint/muscle aches, fluid retention, and hypersensitivity reactions (~4%). Because it raises GH, it can worsen glucose tolerance, so blood sugar (and diabetes/retinopathy risk) needs monitoring.

Contraindications on the FDA label include pregnancy, active malignancy, and disruption of the hypothalamic-pituitary axis (pituitary tumor/surgery/radiation/trauma); it is not for weight loss in the general population. Unapproved 'research' tesamorelin carries additional risks — no quality control, possible contamination, mislabeling, and no medical oversight.

💰

PRICE ALERTS

Track Tesamorelin prices

Get an alert when a trusted, tested vendor drops the price. Free.

Frequently asked questions

Is tesamorelin FDA approved?

Yes — approved in 2010 as Egrifta to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, anti-aging, bodybuilding, or cognition.

How is 'research' tesamorelin different from Egrifta?

Egrifta is a regulated pharmaceutical made to strict standards and dispensed by prescription. Grey-market 'research' powders are unapproved, not tested for purity or sterility, and illegal to sell for human use.

Does it work for regular belly fat, not just HIV?

It reliably reduces visceral fat because that fat is GH-sensitive, but its efficacy and safety were only established in HIV-associated lipodystrophy. Broad use is off-label and unstudied for long-term safety.

Can it improve memory or brain function?

One short randomized trial suggested modest executive-function gains in older adults. That's early, preliminary evidence — not an approved or proven cognitive treatment.

Do the fat-loss results last?

Largely no. Visceral fat tends to return after stopping, since the drug works by continuously stimulating GH release rather than causing a permanent change.

Sources

Last reviewed 2026-07-07. This guide is educational and research-focused — not medical advice. Tesamorelin products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.

Related peptides

Or compare prices across all peptides.

Ready to compare Tesamorelin?

See prices across trusted, third-party-tested vendors, normalized per milligram.

Compare Tesamorelin prices →